NIR Group

[stockmasterflash]

He popped up here last year

Don't know what the deal was. Hijack the shell? UNVC was one of the ones named in the SEC complaint as being in long term default to NIR. UNVC hasn't operated in 5 years or so. The CEO was a serious deadbeat. In his personal bankruptcy, he refused to turn over his tax records to the UST. Then when the bankruptcy was denied, Ribotsky gave the company another $60,000.

But that's neither here nor there--no PR's for a year before or after this Bobby sighting. PR.com is a free PR service from what I know. Same time as a fake UNVC website appeared too

http://www.pr.com/press-release/567501

UNIVEC Announces Appointment for Chairman of Financial Advisory Board

Owings Mills, MD, July 03, 2014 --(PR.com)-- Univec, Inc. (UNVC) a specialty pharmaceutical company, announces the appointment for Chairman of the Financial Advisory Board ("CFAB" or "Chairman") Robert M. Cohen of Revolution Investment Management based in New York. Mr. Cohen will be responsible for overseeing operations in finance. With over 32 years in the investment industry Mr. Cohen was Founder and President of Robert M. Cohen and Co., a full service brokerage firm specializing in investment banking , research and marketing making.

David L. Dalton, President and CEO of Univec stated, “We are delighted to have reached this agreement with such a seasoned professional. Mr. Cohen's expertise will lead the company's financial operations and funding process for expanding and moving forward.”

About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes transdermal patches and high cost Specialty Pharmaceuticals. Recent NDC approvals by the FDA provides a niche market for smoking cessation, nicotine replacement products and pain management along with behavioral health pharmaceuticals.

Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed

Univec Inc.
The Specialty Pharmaceutical Company

Contact:
David Dalton, President
Contact Information
Univec Inc.
David Dalton
443-253-0194
Contact